⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
High-throughput Screening (HTS) Market to Grow from USD 27.66 Billion in 2026 to USD 45.90 Billion by 2031, at a CAGR of 10.7% – MarketsandMarkets™
globenewswire.com
TMO
A
MRK
DHR
BIO
CRC
EFSC
CC
Mentari Therapeutics Appoints Industry Veteran Greg Divis as Chief Executive Officer
prnewswire.com
AVDL
ALKS
MRK
SNY
FDA Approves First Oral PCSK9 Inhibitor to Lower LDL Cholesterol in Adults with High Cholesterol
globenewswire.com
MRK
BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026
accessnewswire.com
MRK
Court Upholds Lara's Endorsement Of Insurer Discrimination, Says Consumer Watchdog
prnewswire.com
MRK
Parkinson's Disease Clinical Trial Pipeline Boom as 150+ Companies are in the Race for Better Treatments | DelveInsight
globenewswire.com
ANVS
SUPN
ABBV
VNDA
JAZZ
ACAD
MRK
Merck Opens BioReliance® Testing Facility in Darmstadt, Germany to Support Drug Product Release in Europe
globenewswire.com
MRK
ENT Disorder Treatment Market to Reach US$58 Billion by 2034, Driven by Digital Diagnostics and Minimally Invasive Car
globenewswire.com
GSK
SNY
PFE
AZN
NVS
ABBV
JNJ
MRK
MDT
SN
BSX
TEVA
SUN
Merck’s LIPFENDRA® (enlicitide) is the First and Only Once-Daily Oral PCSK9 Inhibitor Approved by the U.S. FDA to Reduce LDL-C in Adults with Hypercholesterolemia
businesswire.com
MRK
KEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapy
businesswire.com
MRK